Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeting SPMS: Effect of teriflunomide on microglial activation in RRMS
2016-003622-16Phase 4Completed
- Sponsor
- Turku University Hospital
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of teriflunomide in multiple sclerosis (MS) (2 arms), sponsored by Turku University Hospital. Primary endpoints: Change in microglial activity on teriflunomide and Between-cohort comparison of microglial activation. Started Feb 2017; status: completed.
02
Drugs
teriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2016-003622-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003622-16.